Does H. pylori cause fatty liver? This question has generated considerable scientific interest, as both Helicobacter pylori infection and non-alcoholic fatty liver disease (NAFLD) are common conditions affecting millions of people in the UK. H. pylori is a bacterium that colonises the stomach lining, whilst NAFLD involves excessive fat accumulation in the liver. Although some research suggests a possible association between these conditions, the evidence remains inconclusive. Current UK clinical guidelines do not recognise H. pylori as an independent cause of fatty liver disease. Understanding the relationship between these conditions, their distinct risk factors, and when to seek medical advice is essential for appropriate management.

Understanding H. pylori and Fatty Liver Disease

Helicobacter pylori (H. pylori) is a spiral-shaped bacterium that colonises the stomach lining, affecting approximately 20–30% of adults in the UK, with prevalence varying by age, ethnicity, and socioeconomic background. This organism has evolved mechanisms to survive in the acidic gastric environment, producing urease enzyme that neutralises stomach acid locally. H. pylori is primarily associated with peptic ulcer disease, chronic gastritis, and in some cases, gastric cancer. Transmission typically occurs through the faecal-oral or oral-oral route, often via contaminated water or close household contact during childhood.

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver conditions characterised by excessive fat accumulation in hepatocytes (liver cells) in individuals who consume little or no alcohol. NAFLD affects approximately 25–30% of adults in the UK and ranges from simple steatosis (fat accumulation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and potential progression to fibrosis, cirrhosis, or hepatocellular carcinoma. (Note: some organisations now use the terms metabolic dysfunction-associated steatotic liver disease [MASLD] and metabolic dysfunction-associated steatohepatitis [MASH], though current NICE guidance continues to use NAFLD terminology.) The condition is strongly associated with metabolic syndrome, including obesity, type 2 diabetes, dyslipidaemia, and hypertension.

Whilst H. pylori primarily affects the gastrointestinal tract and NAFLD is a hepatic disorder, emerging research has explored potential connections between these two common conditions. Understanding each condition independently is essential before examining whether a causal or associative relationship exists. Both conditions are prevalent in the general population, often asymptomatic in early stages, and can have significant long-term health implications if left unmanaged. The question of whether H. pylori infection contributes to fatty liver development has generated considerable scientific interest, prompting numerous epidemiological and mechanistic studies.

The Link Between H. pylori Infection and Liver Health

The potential relationship between H. pylori infection and liver health extends beyond direct bacterial invasion, as H. pylori does not typically colonise the liver itself. Instead, researchers have investigated several indirect mechanisms through which this gastric pathogen might theoretically influence hepatic metabolism and inflammation. It is important to emphasise that these proposed pathways are based on observational and preclinical studies and do not establish causality.

Systemic inflammation represents one proposed pathway. H. pylori infection triggers chronic low-grade inflammation, with elevated circulating levels of pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP). These inflammatory mediators can affect insulin signalling pathways and lipid metabolism throughout the body, potentially contributing to hepatic steatosis. Chronic inflammation is recognised as a key driver in NAFLD pathogenesis, creating a theoretical link between H. pylori-induced systemic inflammation and liver fat accumulation.

Insulin resistance provides another potential mechanistic connection. Some studies suggest H. pylori infection may worsen insulin resistance through inflammatory pathways and alterations in gut hormone secretion, including ghrelin and leptin. Since insulin resistance is a cornerstone of NAFLD development, any factor that exacerbates insulin sensitivity could theoretically increase fatty liver risk. Additionally, some research has associated H. pylori infection with alterations in lipid profiles, including increased triglycerides and LDL cholesterol, which are established risk factors for NAFLD, though findings are inconsistent.

The gut-liver axis represents an evolving area of research. H. pylori may influence gut microbiota composition and intestinal permeability, potentially affecting the translocation of bacterial products to the liver via the portal circulation. However, these mechanisms remain incompletely understood, and establishing causality rather than mere association requires rigorous investigation. It is important to note that whilst these biological pathways are plausible, they do not confirm that H. pylori directly causes fatty liver disease.

Does H. pylori Cause Fatty Liver? Current Evidence

The scientific evidence regarding whether H. pylori causes fatty liver disease remains inconclusive and controversial. Multiple observational studies have examined this relationship, yielding mixed results that prevent definitive conclusions.

Several meta-analyses and systematic reviews have reported positive associations between H. pylori infection and NAFLD, with some studies suggesting H. pylori-positive individuals have approximately 1.3 to 1.5 times higher odds of having NAFLD compared to uninfected individuals. However, these associations do not establish causation, and many studies have significant methodological limitations, including cross-sectional designs that cannot determine temporal relationships, inadequate adjustment for confounding factors (particularly metabolic syndrome components), and heterogeneous diagnostic criteria for both H. pylori and NAFLD.

Conversely, other well-designed studies have found no significant association between H. pylori infection and fatty liver disease after adjusting for metabolic risk factors. These findings suggest that any observed relationship may be explained by shared risk factors rather than direct causation. Importantly, major UK and European clinical guidelines (including NICE and EASL) do not recognise H. pylori as an independent cause of NAFLD; metabolic risk factors—obesity, insulin resistance, type 2 diabetes, and dyslipidaemia—remain the predominant drivers.

Eradication studies provide limited insight. Small trials examining whether H. pylori eradication improves liver fat content have shown inconsistent results, with most demonstrating no significant benefit on hepatic steatosis or metabolic parameters. This lack of improvement following bacterial eradication further questions a causal relationship. The current position is that whilst H. pylori infection may contribute to the complex multifactorial pathogenesis of NAFLD in susceptible individuals through inflammatory or metabolic pathways, it is not considered a primary or independent cause of fatty liver disease. The predominant drivers of NAFLD remain obesity, insulin resistance, and metabolic syndrome, regardless of H. pylori status.

Risk Factors for Both H. pylori and Fatty Liver

Understanding the shared and distinct risk factors for H. pylori infection and NAFLD helps clarify why these conditions may co-occur without necessarily having a causal relationship.

H. pylori infection risk factors include:

• Socioeconomic factors: Lower socioeconomic status, overcrowded living conditions, and poor sanitation during childhood increase transmission risk

• Geographic origin: Higher prevalence in developing countries and certain ethnic populations

• Age: Infection typically acquired in childhood, with prevalence increasing with age in some cohorts

• Family history: Household transmission is common, particularly from parents to children

NAFLD risk factors include:

• Obesity: Particularly central adiposity, with BMI ≥30 kg/m² significantly increasing risk

• Type 2 diabetes mellitus: Approximately 50–70% of people with type 2 diabetes have NAFLD; conversely, around 20–30% of people with NAFLD have type 2 diabetes, with higher prevalence in those with NASH

• Dyslipidaemia: Elevated triglycerides and low HDL cholesterol

• Metabolic syndrome: The constellation of obesity, hypertension, dyslipidaemia, and insulin resistance

• Age and gender: Risk increases with age; men and postmenopausal women at higher risk

• Ethnicity: Higher prevalence in South Asian populations in the UK; globally, Hispanic/Latino populations also show increased risk

• Sedentary lifestyle: Physical inactivity and poor dietary habits

Overlapping factors that may confound the relationship between these conditions include age, certain ethnic backgrounds, and potentially dietary patterns. Importantly, socioeconomic status may influence both conditions through different mechanisms—affecting H. pylori transmission in childhood whilst also influencing dietary quality and obesity risk. When evaluating individual risk, it is essential to consider these factors independently. A person may have both conditions simply due to their high prevalence in the general population, rather than one causing the other. Addressing modifiable risk factors, particularly those related to metabolic health, remains the cornerstone of NAFLD prevention and management, regardless of H. pylori status.

When to Seek Medical Advice for H. pylori or Liver Concerns

Recognising when to seek medical evaluation is crucial for both H. pylori infection and fatty liver disease, as both conditions are often asymptomatic in early stages.

Seek medical advice for potential H. pylori infection if you experience:

• Persistent or recurrent upper abdominal pain or discomfort

• Unexplained nausea or vomiting

• Loss of appetite or unintentional weight loss

• Bloating or early satiety (feeling full quickly)

• Alarm symptoms requiring urgent assessment: melaena (black, tarry stools), haematemesis (vomiting blood), severe abdominal pain, or unexplained anaemia

Diagnosis in adults typically involves non-invasive testing such as the urea breath test or stool antigen test. Before testing, you should stop proton pump inhibitors (PPIs) for at least 2 weeks and antibiotics or bismuth-containing medicines for at least 4 weeks, where possible, to avoid false-negative results. Blood tests (serology) are not recommended for diagnosing active H. pylori infection in adults. If H. pylori is confirmed, NICE guidelines recommend eradication therapy, typically comprising 7-day triple therapy with a proton pump inhibitor and two antibiotics. The choice of antibiotics (e.g., clarithromycin and amoxicillin, or metronidazole-based regimens) depends on prior macrolide exposure, local antibiotic resistance patterns, and individual allergies. Test-of-cure (confirming eradication) is recommended at least 4 weeks after completing treatment in certain situations, including peptic ulcer disease, gastric MALT lymphoma, or persistent symptoms, using a urea breath test or stool antigen test (again, after withholding PPIs).

Seek medical advice for potential liver concerns if you have:

• Risk factors for NAFLD (obesity, diabetes, metabolic syndrome)

• Abnormal liver function tests detected incidentally

• Persistent fatigue or right upper quadrant discomfort

• Signs of advanced liver disease: jaundice (yellowing of skin/eyes), ascites (abdominal swelling), peripheral oedema, easy bruising, or confusion

NICE recommends using the Enhanced Liver Fibrosis (ELF) test to assess the risk of advanced fibrosis in adults with NAFLD. Many UK clinical pathways (endorsed by the British Society of Gastroenterology and British Association for the Study of the Liver) also use non-invasive scores such as FIB-4 or the NAFLD Fibrosis Score (NFS) as an initial triage tool before proceeding to ELF testing or FibroScan. Liver ultrasound may identify steatosis, though it has limited sensitivity for mild fat accumulation.

Important considerations:

If you have been diagnosed with H. pylori, there is no evidence supporting routine liver screening solely based on this infection. Conversely, if you have NAFLD, H. pylori testing is not routinely indicated unless you have specific gastrointestinal symptoms. Management should focus on addressing metabolic risk factors through lifestyle modification, including weight loss (7–10% body weight target for those with overweight or obesity), increased physical activity (at least 150 minutes of moderate-intensity aerobic activity per week), and dietary improvements following a Mediterranean-style diet. Your GP can coordinate appropriate investigations, provide lifestyle advice, and arrange specialist referral to gastroenterology or hepatology services when indicated, particularly if advanced fibrosis is suspected or liver enzymes remain persistently elevated despite lifestyle interventions. If you experience side effects from any prescribed medicines, you can report these via the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk/.

Frequently Asked Questions